Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $18.4 million.

  • Tango Therapeutics' Total Current Liabilities fell 50.92% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year decrease of 50.92%. This contributed to the annual value of $38.2 million for FY2024, which is 16.91% down from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Total Current Liabilities is $18.4 million, which was down 53.92% from $40.0 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Total Current Liabilities peaked at $55.5 million during Q4 2022, and registered a low of $301,964 during Q1 2021.
  • In the last 3 years, Tango Therapeutics' Total Current Liabilities had a median value of $42.8 million in 2024 and averaged $41.2 million.
  • In the last 5 years, Tango Therapeutics' Total Current Liabilities surged by 36,393.70% in 2021 and then tumbled by 50.92% in 2025.
  • Over the past 5 years, Tango Therapeutics' Total Current Liabilities (Quarterly) stood at $40.7 million in 2021, then skyrocketed by 36.51% to $55.5 million in 2022, then declined by 17.30% to $45.9 million in 2023, then dropped by 16.91% to $38.2 million in 2024, then tumbled by 50.92% to $18.4 million in 2025.
  • Its Total Current Liabilities was $18.4 million in Q3 2025, compared to $40.0 million in Q2 2025 and $35.9 million in Q1 2025.